<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619019</url>
  </required_header>
  <id_info>
    <org_study_id>SM112015</org_study_id>
    <nct_id>NCT02619019</nct_id>
  </id_info>
  <brief_title>Effect of Spinal Dexamethasone During Transuretheral Prostatectomy</brief_title>
  <official_title>Intrathecal Dexamethasone in Patients Undergoing Transuretheral Prostatectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexamethasone, a high-potency, long-acting glucocorticoid, when added to bupivacaine, it
      extended the duration of analgesia. We aim to study the effectiveness of spinal dexamethasone
      in Transuretheral prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal anesthesia for endoscopic urology surgery like transurethral resection of the prostate
      is a well-established technique. Opioids are extensively used as an adjunct to local
      anesthetics in neuraxial blockade to enhance the duration of postoperative analgesia.
      However, worrisome adverse effects like pruritus, urinary retention, postoperative vomiting
      and respiratory depression limit its use. The aim of this study was to investigate the
      effectiveness of Intrathecal dexamethasone as adjunct to local anesthetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shivering</measure>
    <time_frame>150 min after spinal anesthesia</time_frame>
    <description>by shivering score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>150 min after spinal anesthesia</time_frame>
    <description>immediately before the block and then every 15 min after the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>150 min after spinal anesthesia</time_frame>
    <description>immediately before the block and then every 15 min after the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core temperature</measure>
    <time_frame>150 min after spinal anesthesia</time_frame>
    <description>immediately before the block and then every 15 min after the block</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Postspinal Shivering</condition>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pethidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pethidine</intervention_name>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally</description>
    <arm_group_label>Pethidine group</arm_group_label>
    <other_name>Mepredine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 50-75 yr ASA class I,II, and III undergoing Transuretheral prostatectomy under
             spinal anesthesia

        Exclusion Criteria:

          -  Contraindications to spinal anesthesia, Allergy to the study medication, Thyroid
             disease, Parkinson's disease Patients receiving vasodilators or medications likely to
             alter thermoregulation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seham M Moeen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut Univerisity</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seham Mohamed Moeen Ibrahim</name>
      <address>
        <city>Asyut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Seham Mohamed Moeen Ibrahim</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

